Liquid Biopsy Market By Product & Service (Assay Kits, Instruments, Services), By Circulating Biomarkers(Circulating Tumor Cells, Circulating Tumor DNA (ctDNA),Cell-free DNA (cfDNA),Extracellular Vesicles (EVS), Other Circulating Biomarkers), By Application ( Cancer Application and Non-cancer Applications ), By Technology (Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays), By Clinical Application ( Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic & Research Centers, Other),and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa) – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2022 – 2028

Liquid Biopsy Market Overview

Liquid biopsy is a practical, rapid, non-invasive, and reproducible sample procedure that can reflect the changes in tumour gene expression profile, and provide a firm base for customised therapy and early diagnosis of cancer. Furthermore, in recent years, there has been a focus on early cancer screening, tumour progression tracking, measuring therapy response and clinical prognosis, and detecting recurrent and refractory cancers. Furthermore, due to technical advancements in both practicality and turnaround time, liquid biopsy has lately attracted considerable interest as a non-invasive alternative to tissue biopsy in cancer patients.
Due to improvements such as next-generation sequencing for advanced cancer patients in liquid biopsies, an increase in the number of cancer patients, and a rise in patient demand for minimally invasive therapy, the liquid biopsy market is growing. However, in developing regions, a lack of awareness of liquid biopsy limits market growth. On the contrary, rising healthcare spending in developing nations like India and China, as well as the adoption of liquid biopsy testing to treat uncommon malignancies, are likely to drive market growth. 

Market Size

According to Business Intelligence Insights "Liquid Biopsy Market is expected to grow from USD 2394.10 million in 2021 to USD 6365.03 million by 2028, at a CAGR of 17.70 % during the forecast period 2022-2028

Covid -19 Impact Analysis

The unprecedented impact of COVID-19 has been far-reaching, but the impacts on cancer patients make them one of the worst impacted populations. COVID-19 has had a significant impact on the number of patients who are screened, diagnosed, and treated for cancer. Due to the rising number of COVID-19 patients being admitted to hospitals, several hospitals and departments, including cancer clinics, were re-profiled for treating COVID-19 patients. As a result, many diagnostic and treatment operations have been cancelled or postponed around the world, according to one study, including as many as 2.3 million cancer surgeries. Responding to rising cancer incidence has become a pressing medical issue worldwide as a result of the COVID-19 pandemic. COVID-19 has been linked to cancer in a number of cases, hence cancer has been identified as a risk factor for COVID-19. More research is being done in this area to better understand infection dynamics, which is expected to advance the cancer research field. This is expected to boost demand for liquid biopsy products even more. 

Market Dynamics

•    Drivers
o    Cancer incidence and prevalence are increasing.
o    Companion diagnostics are becoming increasingly important 

•    Restraints
o    Certain liquid biopsies have a reduced sensitivity. 

Segmentation Insights

  By Product & Service                                  

The Assay kit is dominating the market with 40 % market share

In 2021, the market for Liquid Biopsy was donated by Assay kit as a Product & Service. Assay kits are a recurring cost due to their normal purchase requirement, which is a major contributor to the segment's growth. Because of the adoption of western lifestyles and choices in economically developed countries, such as smoking, malnutrition, physical inactivity, and fewer births, the cancer burden is predicted to be considerably bigger. The demand for early cancer detection is poised to drive the global market forward. Liquid biopsy was critical for diagnosing solid tissues and other disease

By Circulating Biomarkers

 Circulating Tumor dominated the market with more than 25% of the market share

   The Circulating Biomarkers in which Liquid Biopsy can be taken are Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Extracellular Vesicles (EVS).In the worldwide Liquid Biopsy industry, circulating tumor is the most popular application mode. The market share is more than 25%. Due to an increase in the number of clinically important tests with genomic analyses in recent years, the circulating tumour cell segment generated the most revenue in 2020. Furthermore, due to the rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumour DNA, circulating tumour DNA is predicted to be the fastest expanding category during the forecast period (ctDNA).
 

Segmentation of the Global Liquid Biopsy Market: 

By Product & Service
•    Assay Kits
•    Instruments
•    Services

By Circulating Biomarkers
•    Circulating Tumor Cells
•    Circulating Tumor DNA (ctDNA)
•    Cell-free DNA (cfDNA)
•    Extracellular Vesicles (EVS)
•    Other Circulating Biomarkers

By Application
•    Cancer Application
•    Non-cancer Applications

By Technology
•    Multi-gene Parallel Analysis using NGS
•    Single-gene Analysis using PCR Microarrays

By Clinical Application
•    Early Cancer Screening
•    Therapy Selection
•    Treatment Monitoring
•    Recurrence Monitoring

By End User
•    Reference Laboratories
•    Hospitals and Physician Laboratories
•    Academic & Research Centers
•    Other End Users

By Region
•    North America
o    U.S.
o    Canada
•    Europe 
o    Germany
o    U.K.
o    France
o    Italy
o    Spain
o    Rest of Europe
•    Asia Pacific 
o    China
o    India
o    Japan
o    Rest of Asia Pacific
•    Latin America 
o    Brazil
o    Mexico
o    Rest of Latin America
•    Middle East and Africa 
o    UAE
o    South Africa
o    Rest of Middle East and Africa (MEA)

Key Players

List of Key Players in the Global Liquid Biopsy Market:

•    F. Hoffmann-La Roche Ltd. (Switzerland)
•    Myriad Genetics, Inc. (US)
•    QIAGEN N.V. (Netherlands) 
•    Thermo Fisher Scientific, Inc. (US)
•    Guardant Health, Inc. (US)
•    MDxHealth SA (Belgium)
•    Exact Sciences Corporation (US)
•    Illumina Inc. (US)
•    Sysmex Inostics (US)
•    Bio-Rad Laboratories, Inc. (US)
•    Biocept, Inc. (US)
•    NeoGenomics, Inc. (US)
•     ANGLE plc (UK)
•    Menarini-Silicon Biosystems (Italy)
•    Vortex Biosciences, Inc. (US)
•    Exosome Diagnostics, Inc. (US)
•    Agena Bioscience, Inc. (US)
•    MedGenome Inc. (US)
•    Epigenomics AG (Germany)
•    Personal Genome Diagnostics, Inc. (US)

Regional Insights

                                                                North America dominated the market with more than 51% of the market share 

In 2020, North America dominated the market in 2021. Because of higher investments and the presence of a number of biotechnology businesses producing the tests, the United States leads the regional market. Liquid biopsy is supported by a number of organisations, including the American Society of Clinical Oncology (ASCO). As a result, market growth in this region is expected to accelerate. Canada has followed the United States in adopting liquid biopsy tests, allowing FDA-approved tests to be utilized in the country. Furthermore, there are numerous biotechnology businesses operating in the market, which is projected to fuel market expansion throughout the forecast period. The government's increased subsidies and investments in the development of liquid biopsy tests are projected to improve the country's market. 

Table

Report Attributes	Details
Market Size Value in 2021	USD 2394.10 million
Market Size Value in 2028	USD 6365.03 million
Growth Rate	+17.70 %
Base Year	2021
Forecast Period	2022 – 2028
Historical Data	2018-2020
Forecast Units	(USD Million)
Countries Covered	North America, U.S., Canada, Europe, Germany, U.K., France, Italy, Spain, Rest of Europe, Asia Pacific, China, India, Japan, Rest of Asia Pacific, Latin America, Brazil, Mexico, Rest of Latin America, Middle East and Africa, UAE, South Africa, Rest of Middle East and Africa (MEA)
Segments Covered	By Product & Service, By By Circulating Biomarkers, By Clinical Application, By Application, By Technology, By End User, By Region
Competitive landscape	Leading companies, Competitive strategies and Consumer engagement scope
Customization is available	If our report does not contain the information you require, you can contact our experts to have segments created for you. Please contact us at sales@businessintelligence-insights.com if you have any questions

 

Frequently Asked Questions (FAQ):